Rat Target Sites  Mouse Target Sites  TD_{50} (mg/kg/day)  
Male  Female  Male  Female  Rat  Mouse 
ezy lgi mgl nrv per ski sto thy  cli hmo mgl nrv orc sto thy  hag liv lun ski sto  hag mgl ski sub ute  4.28^{m}  34.7^{m} 
Hamster Target Sites  TD_{50} (mg/kg/day) 

Male  Female  
vsc  vsc  56.1^{m} 
Key to the Table Above
The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, longterm animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.
For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD_{50}) and its statistical significance; shape of the doseresponse, author’s opinion as to carcinogenicity, and literature citation.
Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD_{50} estimation for a standard lifespan. See Methods for other details.
TD_{50} provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD_{50} values across chemicals that are rodent carcinogens is more than 100 millionfold. More than half the chemicals tested are positive in at least one experiment.
A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.
Chemical (Synonym) CAS # Species Sex Strain Route Xpo+Xpt PaperNum 0 Dose 1 Dose 2 Dose 3 Dose Literature Reference or NCI/NTP:Site Path Site Path Notes TD50 DR Pval AuOp LoConf UpConf Cntrl 1 Inc 2 Inc 3 Inc Brkly Code
GLYCIDOL 556525 3014 H f syg gav 14m24 2042 0 17.9mg Lijinsky;txih,8,267271;1992 spl hes eh 56.1mg P<.05 + 19.3mg n.s.s. 0/12 4/20 liv hcs e 244.mg P<.4 39.8mg n.s.s. 0/12 1/20 liv cho e 244.mg P<.4 39.8mg n.s.s. 0/12 1/20 lun adc e no dre P=1. 75.3mg n.s.s. 1/12 0/20 tba tum e 71.8mg P<.8 8.94mg n.s.s. 7/12 13/20 3015 H m syg gav 14m24 2042 0 15.8mg for mal e 64.1mg P<.08 19.4mg n.s.s. 0/12 3/19 spl hes eh 99.1mg P<.2 + 24.3mg n.s.s. 0/12 2/19 liv hes e 204.mg P<.4 33.2mg n.s.s. 0/12 1/19 tba tum e no dre P=1. 14.0mg n.s.s. 7/12 9/19 3016 M f b6c gav 24m24 TR374 : 0 17.7mg 35.4mg MXB MXB 15.3mg * P<.0005 10.2mg 26.6mg 5/50 21/50 37/50 hag:acn,adn; mgl:acn,adn,fba; ski:sqc,sqp; sub:fbs,srn; ute:acn,can. C hag MXA 32.9mg * P<.0005 c 18.2mg 103.mg 4/50 11/50 17/50 hag:acn,adn. hag adn 36.0mg * P<.0005 19.4mg 128.mg 4/50 10/50 16/50 S mgl acn 56.6mg * P<.0005 31.5mg 138.mg 1/50 5/50 15/50 S mgl MXA 56.9mg * P<.0005 c 31.0mg 170.mg 2/50 6/50 15/50 mgl:acn,adn,fba. sub MXA 86.4mg * P<.0005 c 43.1mg 229.mg 0/50 3/50 9/50 sub:fbs,srn. sub srn 145.mg * P<.003 60.9mg 702.mg 0/50 1/50 6/50 S ute MXA 127.mg * P<.02 c 51.3mg n.s.s. 0/50 3/50 3/50 ute:acn,can. MXA MXA 137.mg * P<.04 52.6mg n.s.s. 1/50 3/50 5/50 liv:hem,hes; ova:hem; pec:hes; sub:hes; ute:hem,hes. S ute acn 144.mg * P<.04 54.8mg n.s.s. 0/50 3/50 2/50 S sub fbs 217.mg * P<.03 78.1mg n.s.s. 0/50 2/50 3/50 S ski MXA 417.mg * P<.07 c 102.mg n.s.s. 0/50 0/50 2/50 ski:sqc,sqp. TBA MXB 27.5mg * P<.08 10.9mg n.s.s. 45/50 46/50 47/50 liv MXB 76.0mg * P<.07 29.1mg n.s.s. 9/50 7/50 14/50 liv:hpa,hpc,nnd. lun MXB 96.7mg * P<.2 32.3mg n.s.s. 6/50 10/50 8/50 lun:a/a,a/c. 3017 M m b6c gav 24m24 TR374 : 0 17.7mg 35.4mg hag MXA 41.7mg * P<.003 c 21.5mg 270.mg 8/50 12/50 22/50 hag:acn,adn. for sqp 97.5mg * P<.0005 48.3mg 274.mg 0/50 2/50 9/50 S for MXA 100.mg * P<.003 c 47.7mg 533.mg 1/50 2/50 10/50 for:sqc,sqp. MXB MXB 29.2mg * P<.05 12.3mg n.s.s. 35/50 41/50 46/50 for:sqc,sqp; hag:acn,adn; liv:hpa,hpc; lun:a/a,a/c; ski: sqp. C liv MXA 36.6mg * P<.04 c 15.8mg n.s.s. 24/50 31/50 35/50 liv:hpa,hpc. MXA MXA 38.8mg \ P<.03 15.4mg n.s.s. 5/50 12/50 (7/50) mul:mlh,mlm,mlp; thm:mlm. S liv hpa 41.2mg * P<.03 18.4mg n.s.s. 18/50 16/50 30/50 S hag adn 60.4mg * P<.03 27.2mg n.s.s. 7/50 10/50 16/50 S lun MXA 66.2mg * P<.07 c 26.2mg n.s.s. 13/50 11/50 21/50 lun:a/a,a/c. hag acn 148.mg * P<.02 61.5mg n.s.s. 1/50 2/50 7/50 S ski sqp 253.mg * P<.02 c 86.5mg n.s.s. 0/50 0/50 4/50 mul mlh 297.mg * P<.04 100.mg n.s.s. 0/50 1/50 3/50 S epy srn 473.mg * P<.09 e 116.mg n.s.s. 0/50 0/50 2/50 ubl tcc 761.mg * P<.3 e 186.mg n.s.s. 0/50 1/50 1/50 TBA MXB 34.6mg * P<.2 12.6mg n.s.s. 42/50 47/50 49/50 liv MXB 36.6mg * P<.04 15.8mg n.s.s. 24/50 31/50 35/50 liv:hpa,hpc,nnd. lun MXB 66.2mg * P<.07 26.2mg n.s.s. 13/50 11/50 21/50 lun:a/a,a/c. 3018 R f f34 gav 23m24 TR374 : 0 26.5mg 53.6mg MXB MXB a 4.13mg / P<.0005 2.43mg 7.45mg 25/50 39/50 42/50 bra:gln; cli:acn,adn,can; for:sqc,sqp; mgl:acn,fba; mth: sqc,sqp; mul:mnl; thy:fca,fcc; ton:sqp. C mgl MXA a 4.15mg / P<.0005 c 2.40mg 7.58mg 14/50 34/50 37/50 mgl:acn,fba. mgl fba a 4.55mg * P<.0005 c 2.52mg 8.70mg 14/50 32/50 29/50 cli MXA a 12.5mg / P<.0005 c 5.27mg 36.5mg 5/50 9/50 12/50 cli:acn,adn,can. ute esp a 13.5mg * P<.0005 6.57mg 39.2mg 19/50 21/50 14/50 S mul mnl a 14.0mg / P<.0005 c 7.12mg 32.9mg 13/50 14/50 20/50 cli adn a 16.7mg * P<.0005 6.73mg 56.7mg 3/50 7/50 7/50 S mgl acn a 23.0mg * P<.0005 c 11.9mg 46.8mg 1/50 11/50 16/50 for MXA a 28.5mg / P<.0005 c 11.0mg 62.5mg 0/50 4/50 11/50 for:sqc,sqp. for sqp a 31.4mg / P<.0005 11.3mg 77.8mg 0/50 4/50 8/50 S bra gln a 43.6mg * P<.0005 c 12.3mg 174.mg 0/50 4/50 4/50 MXA MXA a 44.7mg * P<.0005 c 14.1mg 181.mg 1/50 3/50 7/50 mth:sqc,sqp; ton:sqp. MXA sqp a 46.7mg * P<.0005 14.4mg 212.mg 1/50 3/50 6/50 mth:sqp; ton:sqp. S ton sqp a 53.7mg * P<.0005 15.1mg 319.mg 1/50 3/50 5/50 S cli MXA a 62.7mg * P<.008 14.0mg 2.21gm 2/50 2/50 5/50 cli:acn,can. S cli can a 64.1mg * P<.008 14.1mg 2.38gm 2/50 1/50 5/50 S thy MXA a 68.2mg * P<.003 c 13.1mg 878.mg 0/50 1/50 3/50 thy:fca,fcc. pta adn a 30.6mg * P<.03 10.0mg n.s.s. 18/50 14/50 6/50 S sub MXA a 71.1mg * P<.02 15.8mg n.s.s. 1/50 4/50 2/50 sub:fbs,fib. S adr MXA a 91.1mg / P<.04 17.7mg n.s.s. 2/50 0/50 3/50 adr:con,crn. S ute MXA a 130.mg / P<.02 20.1mg n.s.s. 1/50 0/50 4/50 ute:acn,adn. S for sqc a 317.mg * P<.02 94.6mg n.s.s. 0/50 0/50 3/50 S thy fcc a 411.mg * P<.02 109.mg n.s.s. 0/50 0/50 3/50 S stg fbs a 752.mg * P<.07 e 164.mg n.s.s. 0/50 0/50 2/50 TBA MXB a 3.88mg / P<.0005 2.29mg 7.16mg 43/50 43/50 47/50 liv MXB a no dre P=1. n.s.s. n.s.s. 0/50 0/50 0/50 liv:hpa,hpc,nnd. 3019 R m f34 gav 93w98 TR374 : 0 26.8mg 53.6mg tes ict a 1.49mg / P<.0005 .818mg 2.82mg 46/50 50/50 49/50 S MXB MXB a 2.30mg / P<.0005 1.04mg 4.74mg 8/50 40/50 46/50 bra:gln; col:adc,adp; for:sqc,sqp; mgl:fba; ski:bct,sea, sec; smi:mua; thy:fca,fcc; tnv:men,msm; zym:can. C mul mnl a 3.14mg / P<.0005 1.49mg 6.95mg 25/50 33/50 21/50 S tnv MXA a 4.42mg / P<.0005 c 1.75mg 8.36mg 3/50 34/50 39/50 tnv:men,msm. tnv msm a 5.68mg / P<.0005 1.94mg 12.1mg 3/50 24/50 31/50 S ski sqp a 7.00mg * P<.0005 1.31mg 80.1mg 0/50 3/50 3/50 S bra gln a 7.32mg * P<.0005 c 1.31mg 74.5mg 0/50 5/50 6/50 mgl fba a 7.97mg / P<.0005 c 2.65mg 27.8mg 3/50 8/50 7/50 lun MXA a 10.7mg * P<.0005 2.61mg 70.1mg 2/50 5/50 4/50 lun:a/a,a/c. S pre adn a 10.8mg * P<.002 2.87mg 85.3mg 5/50 7/50 1/50 S pre MXA a 11.2mg / P<.0005 3.43mg 68.2mg 10/50 7/50 5/50 pre:acn,adn. S pta MXA a 11.9mg * P<.005 2.94mg 205.mg 8/50 8/50 2/50 pta:adn,can. S pta adn a 13.1mg * P<.009 3.08mg 767.mg 8/50 7/50 2/50 S thy MXA a 16.5mg / P<.0005 c 3.45mg 81.4mg 1/50 4/50 6/50 thy:fca,fcc. lun a/a a 17.0mg * P<.003 3.07mg 344.mg 1/50 3/50 2/50 S thy fcc a 19.7mg / P<.0005 3.46mg 147.mg 1/50 2/50 5/50 S ski ker a 21.6mg * P<.003 3.55mg 333.mg 1/50 4/50 1/50 S sub MXA a 25.3mg / P<.0005 6.08mg 160.mg 4/50 5/50 5/50 sub:fbs,fib,nfm. S for MXA a 25.6mg / P<.0005 c 3.64mg 194.mg 1/50 2/50 6/50 for:sqc,sqp. tnv men a 25.8mg * P<.0005 10.8mg 61.5mg 0/50 10/50 8/50 S ski MXA a 29.5mg / P<.0005 c 10.2mg 87.2mg 0/50 5/50 4/50 ski:bct,sea,sec. sub MXA a 30.0mg / P<.002 6.33mg 248.mg 4/50 4/50 5/50 sub:fbs,fib. S ski MXA a 30.6mg * P<.0005 10.3mg 98.1mg 0/50 5/50 3/50 ski:bct,sea. S ton MXA a 37.8mg * P<.006 3.94mg 1.42gm 1/50 1/50 4/50 ton:sqc,sqp. S ski bct a 38.8mg * P<.0005 11.1mg 176.mg 0/50 4/50 2/50 S thy cca a 42.8mg / P<.005 7.41mg 651.mg 2/50 3/50 3/50 S sub MXA a 42.9mg / P<.002 8.90mg 377.mg 2/50 3/50 4/50 sub:fib,nfm. S zym can a 49.8mg / P<.0005 c 14.7mg 235.mg 1/50 3/50 6/50 sub fib a 55.9mg / P<.005 9.83mg 942.mg 2/50 2/50 4/50 S for sqp a 101.mg / P<.0005 35.5mg 395.mg 0/50 1/50 5/50 S MXA MXA a 244.mg * P<.004 c 89.0mg 1.88gm 0/50 1/50 4/50 col:adc,adp; smi:mua. MXA MXA a 72.3mg * P<.03 8.91mg n.s.s. 3/50 2/50 5/50 mth:sqc,sqp; ton:sqc,sqp. S TBA MXB a 1.66mg / P<.0005 .903mg 3.17mg 43/50 50/50 48/50 liv MXB a 101.mg * P<.2 16.6mg n.s.s. 1/50 1/50 1/50 liv:hpa,hpc,nnd.
See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.
A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.
For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.
The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.
A Supplementary Dataset gives details on dosing and survival for each experiment.
Relatively precise estimates of the lower confidence limit on the TD_{10} (LTD_{10}) are readily calculated from the TD_{50} and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD_{10} values, we provide them in an Excel spreadsheet.
PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.